Ruth Ann Mathew Kalathil

cardiology fellow @ University of Cincinnati

[Ruth Ann Mathew Kalathil @RuthAnnMathew]

ESC London. Excited to present our paper on outcomes of atrial fibrillation in heart failure. #ESCCongress

[M. Tanveer Uddin, MD @TanveerUddinMD]

What an incredible crew — excited to welcome our newest Cardiology Fellows! 🎉 @uccardiology @uofcincy

[UC Cardiology @uccardiology]

University of Cincinnati Division of Cardiovascular Health and Disease would like to welcome and congratulate all trainees that matched in our Cardiovascular Disease, Cardiac Electrophysiology, & Interventional Cardiology fellowship programs. @UCincyMedicine @uc_health

[Saraschandra Vallabhajosyula, MD MSc @SarasVallabhMD]

It was truly one of the greatest honors of my life to serve as the inaugural @Creighton University Alumni Visiting Lecturer. Loved my 1.5 days in Omaha, connecting with old friends and teachers, and discussing #MDT in acute CV care. Many thanks to the DOM for the opportunity.

[Ruth Ann Mathew Kalathil @RuthAnnMathew]

Fantastic panel discussion on INOCA today .Engaging insights from all the experts, including @purviparwani made for a thought-provoking session. It was a pleasure chatting with you. #Cardiology #ESCCongress2024

[Davide Capodanno @DFCapodanno]

How many times have we seen this flow chart on the duration of DAPT change over the years? Let’s summarize the situation regarding class I recommendations (“must be done”) as reported in the new 2024 guidelines on chronic coronary syndromes:
- High bleeding risk patient: DAPT for 1-3 months.
- High ischemic risk patient with no high bleeding risk: DAPT for 6 months (alternatively 1-6 months in class IIb).
- Patient with neither high ischemic risk nor high bleeding risk: DAPT for 6 months (alternatively 1-3 months in class IIb).
I believe there is a missed opportunity for a recommendation regarding 'bi-risk' patients, but there is little evidence on this matter.
https://t.co/7RI6XRsdrd #ESCCongress

[Dr. Purvi Parwani @purviparwani]

#ESCcongress
#AF guidelines
What’s new?➡️

🆕 importance of optimal care according to the new AF-CARE pathway,

C] Comorbidity and risk factor management;
A] Avoid stroke and thromboembolism;
R] Reduce symptoms by rate and rhythm control;
E] Evaluation and dynamic reassessment.

🆕 broader application of appropriate anticoagulant therapy, and using the CHA2DS2-VA score to assist in decision-making

🆕 ‘safety-first' approach -
keep safety and anticoagulation in mind when considering rhythm control; e.g. delay cardioversion and provide at least 3 weeks of anticoagulation beforehand if AF duration >24 h, and consider toxicity and drug interactions for antiarrhythmic therapy.

🆕 integrating rate and rhythm control, with shared-decision making on referral for catheter and surgical ablation.

➡️Oral anticoagulants: recommended for all eligible patients, except those at low risk of incident stroke or thromboembolism (CHA2DS2-VA = 1 anticoagulation should be considered; CHA2DS2-VA ≥2 anticoagulation recommended).

➡️ Catheter ablation: consider as second-line option if antiarrhythmic drugs fail to control AF, or first-line option in patients with paroxysmal AF.

https://t.co/vTP5JDvUtE

#Eppeeps @mirvatalasnag

#ESCCongress

[Erik Rafflenbeul @KardiologieHH]

The Sc is gone...
...#CHA2DS2-VA

New ESC #Afib guidelines presented at #ESCcongress

[C. Michael Gibson MD @CMichaelGibson]

ABYSS trial showed interrupting B-blocker in MI with preserved LVEF > 40% is not different from continuing B-blockers with regards to composite of death, MI, stroke, or CV hospitalization. Interrupting B-blockers resulted in higher hospitalization rate #ESCCongress #cardiology

[Ruth Ann Mathew Kalathil @RuthAnnMathew]

Finally submitted my cardiology fellowship application! Grateful beyond words for all the mentorship. Here’s to new challenges and opportunities. Godspeed! #Cardiology #fellowship

[Saraschandra Vallabhajosyula, MD MSc @SarasVallabhMD]

Congrats to @RuthAnnMathew and @Dr_Akshay_MB for leading this important analysis! @BrownMedicine @BrownCardiology

[Akshay Machanahalli Balakrishna, MD @Dr_Akshay_MB]

Is there a role of PCI in ischemic cardiomyopathy?

Check out our article on this hot topic🔥@mcpquality

🎯NO difference in all-cause mortality☠️ with PCI revascularization compared to optimal medical therapy

@RuthAnnMathew @AGoldsweig @SarasVallabhMD @kdahal11 #cardiotwitter

[Ruth Ann Mathew Kalathil @RuthAnnMathew]

Excited to share our new paper on PCI Vs medical management in stable CAD with severe LV systolic dysfunction. Grateful to the brilliant minds behind our research. Thank you!

@Dr_Akshay_MB @SarasVallabhMD @AGoldsweig @kdahal11

https://t.co/7ECGiDBeZ0.

[Ruth Ann Mathew Kalathil @RuthAnnMathew]

Our abstract has been accepted for #ESCCongress - can't wait to present it! https://t.co/VIaJtJvhwd

[Atul D. Bali, MD @ABaliMD]

Very important discussion @SCAI re: cross section of IC/HF/CC.

The modern IC is no longer a just coronary operator & needs to be adept with full spectrum of acute🫀care.

Spectacular and inspiring discussion @SrihariNaiduMD @agtruesdell @SarasVallabhMD 👏🏽

#SCAI2024

[Ruth Ann Mathew Kalathil @RuthAnnMathew]

Honored to present our Featured research at SCAI. Outcomes of Mechanical Thrombectomy vs contemporary strategies in intermediate and high risk PE.

https://t.co/wEN2AA1FFY

#SCAI2024 #Jscai

[MyJSCAI @MyJSCAI]

📣Pulmonary Embolism Featured Abstract at #SCAI2024:

💡Outcomes of #MechanicalThrombectomy vs Contemporary Treatments Modalities for Intermediate & High-Risk #PE: A Systematic Review & Metanalysis

➡️https://t.co/2u3rrAOgVM

@Dr_Akshay_MB @PusapatiSuma_Dr @HasaanAhmedMD

[Ruth Ann Mathew Kalathil @RuthAnnMathew]

Microplastics and Nanoplastics in Atheromas and Cardiovascular Events | New England Journal of Medicine https://t.co/KzFNReyNi5

While it is unusual to think of nano plastics in athermomas, preclinical studies have shown adverse clinical outcomes associated with it.

[Ruth Ann Mathew Kalathil @RuthAnnMathew]

#ACC24 non stain LDL reduction

[Ruth Ann Mathew Kalathil @RuthAnnMathew]

Chasing our dreams and shaping the further of cardiac health with these awesome ladies! 🙌 . Shoutout to the phenomenal women leading the charge in cardiology, @KTamirisaMD , chatting with you was truly inspiring!, @DrMarthaGulati, @gina_lundberg.